Uri Ilan received his medical degree from the Hebrew university in 2011 and continued straight into pediatric training at Hadassah Medical center in Jerusalem, Israel, where he graduated in 2016. Following his pediatric training, he started his Pediatric Hematology oncology clinical fellowship at Hadassah and continued it at Birmingham Children’s hospital in the UK.
In 2020, he joined the Den Boer group and started working on his PhD project by developing the international leukemia targeted board (iLTB), a European collaboration in which molecular, immune and drug sensitivity data of relapsed and refractory children with leukemia will be reviewed by an expert panel to prioritize which characteristics of a patient’s leukemic cells are the most likely targets for treatment. With this initiative we aim to find the right trial for the right patient and increase the number of patients eligible for drug development studies. This work is performed in collaboration with Prof. dr. Michel Zwaan, head trial and data center of the Princess Máxima Center.